Tagged with CRO,

Pharma Yann Quentric has assumed new responsibilities as president of Iris Pharma; leading the first CRO to specialize exclusively in ophthalmology. From the company’s humble beginnings in southern France to its current international reach, Mr. Quentric shares his vision on the next chapter for the company. Can you start by introducing Iris Pharma…

Pharma While functional outsourcing may be common for companies seeking services from CROs, Medpace believes that their robust, physician-led, full-service business model is the most efficient way to conduct clinical research. Clinical Trial Manager, Patrick Winkler, and Senior Business Development Executive, Geoffrey Bilon, share the service offerings of Medpace, as well…

Pharma Serving as the leader of two companies – Platine, a CRO, and Indicia, a CMO – Stephane Legastelois, in his own words, challenges himself by wearing two different hats. Offering his unique views from two angles of the healthcare industry, Mr. Legastelois opens up as to why France, and particularly…

Pharma Peter Schoevers, CEO and co-founder of Julius Clinical, explains how this innovative and thriving organization allies the academic strength of an ARO with the business-oriented leadership of a CRO. Julius Clinical aims to become the partner of choice for the pharmaceutical industry by strengthening clinical trial credibility, enhancing its quality…

pharma The founder and managing director of LT Clinical Research, one of the first wholly black-owned South African CRO, reveals how South Africa is a very conducive environment for CROs, with a diverse patient population, a well-established regulatory framework and a currency that compares well to other African currencies; why the…

France The President of France’s Association for CROs (AFCROs) discusses the issues surrounding France’s clinical research sector and the actions that both the public and private sector need to take to maintain their competitiveness. He also discusses his company’s recent merger with Biostatem and their mission to internationalize. While France remains…

clinical trials ACLIRES’ senior vice president explains the organization’s ambitions to promote Thailand as a unique place for early phase studies, the company’s partnership with Mahidol University and Siriraj Hospital and its dedication to the development of medicine for Thailand, the region and the world.   What brought you to work at ACLIRES?…

CRO Omega CRO has evolved from its beginnings as a CRO contracted by local and multinational pharmaceutical companies into an organization leading clinical, epidemiological and observational studies of public interest across Turkey. CEO Berk Özdemir discusses the highlights of these studies, including a giant EU 7th Framework project EU-GEI study on…

Parexel Claudio Soto, general manager of PAREXEL Mexico, discusses how the clinical research process required to receive approval for a new clinical protocol in Mexico is fairly straightforward compared to other countries in Latin America. She also addresses the government´s increasing awareness of the importance of their role in helping to…

CRO The directors of one of the leading in country contract research organisations, explain exactly what makes Romania such an attractive destination for clinical trials. They also give some indications of how the already booming clinical research is expected to thrive, and how there will remain plenty of work for all.…

CRO The directors of one of the leading in country contract research organisations, explain exactly what makes Romania such an attractive destination for clinical trials. They also give some indications of how the already booming clinical research is expected to thrive, and how there will remain plenty of work for all.…

CRO The general manager of one of the leading CROs in Romania explains how the country in gathering pace as a top tier clinical trials destination country within the region and how the priority is now about on-time project delivery. Could you please start by introducing PSI and its engagement with…